



DOCKET NO.: 220316US0PCT

RECEIVED
APR 11 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Steven ARKINSTALL, ET AL.

088,090

SERIAL NO.: 10/888,090

: GROUP ART UNIT: 1625

:

FILED: June 21, 2002

: EXAMINER: CHANG, Celia C.

FOR: PHARMACEUTICALLY ACTIVE
SULFONYL AMINO ACID
DERIVATIVES

8/Election
w/traverse

Bet
4-22-03

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated March 10, 2003, Applicants elect, with traverse, Group I, Claims 7-8 and 24-25, for further prosecution. In addition, Applicants elect, with traverse, the compound of example 1 (page 27, lines 18-19 of the specification), 4-chloro-N-({5-[({2-[{2-{{3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}-ethyl}amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl) benzamide as a single disclosed species. Claims 1-4, 6-7, 9-21, 23-28 read on the elected species. Claims 1-4, 6-7, 10-21, 23-24, and 26-28 are generic.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 7-8 and 24-25, drawn to compounds wherein R⁵ and R⁶ are independent substituents; and